Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kailera Therapeutics, Inc. - Common stock (NQ:KLRA)

11.53 -0.18 (-1.54%)
Delayed Quote Updated: 1:47 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kailera Therapeutics, Inc. - Common stock

News headline image
Kailera Therapeutics to Participate in September Investor Conferences
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization 
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
From Kailera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Kailera Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.